Stains remain the first therapeutic approach in patients with dyslipidemia to control plasma lipids levels and cardiovascular risk. Multiple clinical trials have demonstrated the benefits of statins in reducing major cardiovascular adverse events in primary and secondary prevention. Moreover, in patients with coronary artery disease, statins decrease coronary atherosclerotic plaque volume and composition, inducing atheroma stabilization. Pitavastatin, is a new-generation lipophilic statin, indicated for the treatment of dyslipidemia and prevention of cardiovascular diseases. The purpose of this review, the first at our knowledge on this topic, is to summarize and examine the current knowledge about the effectiveness of pitavastatin in patients with coronary artery disease. The available data suggest that pitavastatin significantly, lowers the rate of adverse cardiovascular events, in patients at a high risk of atherosclerotic disease, with stable angina pectoris or with acute coronary syndrome. Moreover intravascular ultrasound have shown that pitavastatin induces favorable changes in plaque morphology, increasing the fibrous cap thickness, and decreasing both plaque and lipid volume indexes. Globally the efficacy of pitavastatin is greater or similar to other statins.

Fici, F., Faikoglu, G., Tarim, B., Robles, N., Tsioufis, K., Grassi, G., et al. (2022). Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION [10.1007/s40292-021-00496-0].

Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention

Grassi G.;
2022

Abstract

Stains remain the first therapeutic approach in patients with dyslipidemia to control plasma lipids levels and cardiovascular risk. Multiple clinical trials have demonstrated the benefits of statins in reducing major cardiovascular adverse events in primary and secondary prevention. Moreover, in patients with coronary artery disease, statins decrease coronary atherosclerotic plaque volume and composition, inducing atheroma stabilization. Pitavastatin, is a new-generation lipophilic statin, indicated for the treatment of dyslipidemia and prevention of cardiovascular diseases. The purpose of this review, the first at our knowledge on this topic, is to summarize and examine the current knowledge about the effectiveness of pitavastatin in patients with coronary artery disease. The available data suggest that pitavastatin significantly, lowers the rate of adverse cardiovascular events, in patients at a high risk of atherosclerotic disease, with stable angina pectoris or with acute coronary syndrome. Moreover intravascular ultrasound have shown that pitavastatin induces favorable changes in plaque morphology, increasing the fibrous cap thickness, and decreasing both plaque and lipid volume indexes. Globally the efficacy of pitavastatin is greater or similar to other statins.
Articolo in rivista - Review Essay
Atherosclerotic plaque; Cardiovascular prevention; Dyslipidemia; Pitavastatin; Thin cap fibroatheroma;
English
Fici, F., Faikoglu, G., Tarim, B., Robles, N., Tsioufis, K., Grassi, G., et al. (2022). Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION [10.1007/s40292-021-00496-0].
Fici, F; Faikoglu, G; Tarim, B; Robles, N; Tsioufis, K; Grassi, G; Gungor, B
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/356098
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact